An update from 4DMedical Ltd ( (AU:4DX) ) is now available.
4DMedical Limited announced a change in the directors’ interests due to the expiry of options on March 1, 2025, involving directors Andreas Fouras and Julian Sutton. Importantly, no securities held by these directors or their related parties have been sold, indicating a stable position in their holdings. This announcement is part of routine disclosures under ASX listing rules and does not imply any immediate impact on the company’s operations or market strategy.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global leader in medical technology, specializing in respiratory care through advanced imaging and AI-powered solutions. Their patented XV Technology® and FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) provide detailed insights into lung function, facilitating early and precise diagnoses of respiratory diseases. The company operates on a Software as a Service (SaaS) model, integrating its solutions into existing hospital infrastructures. In December 2023, 4DMedical expanded its capabilities by acquiring Imbio, enhancing its AI-driven platforms for chronic lung and cardiothoracic diseases.
YTD Price Performance: -19.79%
Average Trading Volume: 957,842
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$164.4M
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.